Introduction
Type 2 diabetes (which is almost always associated with cardiovascular involvement), shows an uncontrollable upward trend, as seen in the latest data published by the WHO (Global Report on Diabetes: http://www.who.int/diabetes/global-report). Individuals with chronically elevated glucose and/or insulin levels, as is present in most patients with type 2 diabetes, have accelerated atherosclerosis and are also prone to acute vascular events [1] . Type 2 diabetes is also associated with disturbances in haemostasis that could contribute to the development of diabetic vascular disease [2] [3] [4] . These pandemic increases in numbers with cardiovascular co-morbidities, including atherothrombotic events and higher incidence of coronary artery disease, are mainly because of the increasing obesity tendency. All of the mentioned co-morbidities are frequently associated with a worse prognosis in type 2 diabetes patients, compared with non-diabetic patients [5] .
The classical view of the main role of tissue factor (TF) as the initiator of the coagulation cascade has to be reassessed, as it is also a mediator in the pathogenesis of cardiovascular disorders [6, 7] . Atherosclerosis contributory risk factors such as smoking, hypertension, hyperlipidaemia and diabetes all increase TF expression [8, 9] . The discovery of blood-borne TF has changed the opinion of labelling vessel-wall TF as the major determinant of thrombosis as emerging studies have recognised a hypercoagulable state associated with an increased circulating TF activity with the development of the concept of 'vulnerable blood' [10] . In addition, it has been shown that this circulating pool of TF in blood that is associated with cells and microparticles is thrombogenic [11] is elevated in type 2 diabetes mellitus [12] .
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Under physiological conditions, the production/activation of prothrombotic and fibrinolytic factors are finely tuned and well balanced, so that haemostasis is appropriate, sufficient to protect from bleeding yet adequately suppressed to prevent pathological thrombosis. However, in diabetes, this fine balance is disturbed and tipped towards a prothrombotic/hypofibrinolytic phenotype which, in association with atheromatous vascular changes and platelet hyperactivity, poses an increased predisposition to cardiovascular ischaemic events [4] .
Multiple mechanisms have been implicated, but particularly pathological changes of the coagulation and resulting abnormal fibrinolysis, feature prominently in type 2 diabetes [13] . The study by Vaidyula and co-workers tested the hypothesis that hyperglycaemia and/or hyperinsulinemia singly or combined may increase TF, and highlighted the following results: (a) in healthy volunteers, combined elevation of plasma insulin and glucose levels for 24 h produced (b) a nine fold increase in circulating tissue factor procoagulant activity (TFPCA) associated with an increase in monocyte TF surface expression and mRNA and (c) changes in other components of blood coagulation [1] . Despite treatment with the recommended dual antiplatelet therapy to treat these coagulation pathologies, there is still an increased atherothrombotic risk in these patients. This may partly be due to abnormal endothelial function, abnormal platelet haemostasis resulting in platelet hyperactivity and/or a general dysregulation of the coagulation process [14] . It is thus evident that more effective therapies and novel markers as well as additional disease tracking methods are warranted for this group of high-risk patients. In this paper, we look at TF levels of two groups of type 2 diabetic patients, those with and those without cardiovascular complications.
Materials and methods
42 diabetic subjects were recruited from the Steve Biko Academic Hospital, diabetic clinic in South Africa. Ethical clearance was obtained for this study from the University of Pretoria Human Ethics Committee. Informed consent was obtained from all participants. Inclusion criteria included (a) subjects older than 18 years and willing to provide informed consent, (b) subjects with known diagnosis of diabetes, (c) for the cardiovascular group, history of previous myocardial infarction, peripheral arterial disease, stroke or coronary arterial bypass grafting. Exclusion criteria included (a) subjects hemodynamically unstable and (b) subjected with documented life threatening disease (malignancy, HIV/AIDS). Two groups were distinguished, 20 diabetics with cardiovascular disease (CVD) and 22 without CVD. The ELISA assay (IMUBIND tissue factor ELISA kit No. 845, American Diagnostica Inc., Stamford) was used for the quantitative determination of human TF, in plasma at an absorbance at 450 nm and comparing the values with those of a standard curve. Final measurements were calculated by deducting the background average of the blanks from the standards and sample readings. A standard curve was drawn by plotting the mean absorbance for each TF standard against the corresponding concentration of TF. The level of TF was expressed in pg mL −1 . The control values quoted were taken from a study performed by Ruszkowska-Ciastek et al. which investigated the low-grade risk of hypercoagulable state in type 2 diabetic patients. The test used in the latter study was the same IMUBIND TF kit used in this current study [15] .
All statistical analyses were performed using the GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, http://www.graphpad.com. Mann-Whitney test was used to compare the two diabetic groups, with a P ≤ .05 considered significant.
Results
Baseline demographic data and clinical characteristics of the study population are shown in Table 1 . The CVD group was slightly older than the group without CVD, mean age of 61 and 53 years, respectively. It is notable to observe that both groups had uncontrolled glucose as evidenced by HBA1c values. Details of the chronic medication taken by patients are also shown. Our results in Table 1 indicate that the concentration of TF was increased in both diabetic groups (with and without CVD) when compared to normal values; however, there was no significant difference between diabetics without CVD and diabetics with CVD. However, the TF values in both diabetic groups were almost two and a half times greater than the control value.
Discussion
According to the International Diabetic Federation, the number of people with diabetes worldwide is increasing and by 2030 this will have risen to 552 million. Individuals with chronically elevated glucose and/or insulin levels, as is present in most patients with type 2 diabetes, have accelerated atherosclerosis and are prone to acute vascular events [1] . Evidence shows that diabetes has been considered to have a prothrombotic status. Characteristic findings in type 2 diabetes include increased coagulation, impaired fibrinolysis, endothelial dysfunction and platelet hyper-reactivity [16] . Increased coagulation can be ascribed to the increased concentration of TF, FVIII, thrombin and fibrinogen [3, 4] . Other mechanisms implicated for the prothrombotic milieu in diabetes are that of increased platelet activity which increase thrombin expression [17] . Diabetic subjects are also known to have elevated levels of plasminogen activator inhibitor type I (PAI-1) which contributes to the hypofibrinolysis [18, 19] . Further evidence provided by Boden et al. showed that high levels of TF in poorly controlled type 2 diabetics which feature hyperglycaemia and hyperinsulinemia contribute to the underlying low-grade inflammation [20] . Due to the low-grade inflammation, there is a rise in circulating levels of interleukin-6 (IL-6), fibrinogen and TF expression in vascular cells [17] . In an environment of chronic hyperglycaemia, typical of type 2 diabetes, the binding of advanced glycated end products to their specific receptors creates an intravascular oxidative stress response, culminating in TF expression in vitro [21] . Furthermore, TF was discovered to be an independent factor related to microvascular diabetic complications (microalbuminuria, retinopathy and neuropathy) which is suggestive of endothelial dysfunction rather than procoagulant activity [22] . In diabetic subjects, particularly those with nephropathy, elevated tissue factor pathway inhibitor (TFPI) activity has been documented [23] . Physiologically, TFPI is the key factor in the initial phase of the coagulation pathway mediated by TF, controlling in turn, the production of thrombin which is so crucial in the pathophysiology of atherothrombosis [24] . More importantly, altered TF/TFPI ratio has been associated with the development of atherosclerosis, acute coronary syndrome, disseminated intravascular coagulation, sepsis or thrombotic complications related to malignancies [25, 26] .
The finding in our study of elevated TF levels in both diabetic groups compares favourably with other studies where high TF levels are found in type 2 diabetic subjects [15, 20, 27] . We additionally show that cardiovascular complications in diabetes further increase TF levels. Therefore, the more "inflammatory" the individual, the higher the TF Table 1 Baseline demographic data and clinical characteristics of the study population and TF levels and for type 2 diabetic patients with and without CVD Data expressed as mean ± (SD) or n (%) All values are shown as medians with standard deviation n/a not applicable, HBA1c haemoglobin A1c (not all 42 subjects had this test completed and are available for 50% of the subjects), MI myocardial infarction, PAD peripheral arterial disease, CABG coronary arterial bypass grafting, ACEI angiotensin converting enzyme inhibitor, Caantagonist calcium antagonist a Control values as recently calculated in study done by Ruszkowska-Ciastek et al. [15] 
